Gilead Hepatitis C Pill Leads 27 New U.S. Drug Approvals
This article is for subscribers only.
Gilead Sciences Inc.’s hepatitis C pill Sovaldi led 27 new U.S. drug approvals in 2013, a “breakthrough” therapy being chased by competitors this year.
Gilead’s pill, designed to cut treatment time by about half, was approved under the Food and Drug Administration’s new program that prioritizes reviews of promising medicines. Johnson & Johnson and Pharmacyclics Inc.’s Imbruvica for blood cancer, as well as Roche Holding AG’s Gazyva for chronic lymphocytic leukemia, also gained approval under the new designation.